CNS targeted delivery of anti-HIV drugs

描述(申请人提供)：该计划计划开发一种药物输送系统，提供最大限度的药物暴露，并抑制大脑和中枢神经系统(CNS)组织中残留的人类免疫缺陷病毒(HIV)*。高效抗逆转录病毒联合药物疗法(HAART)的出现将血浆病毒浓度降低到无法检测的水平，并延长了HIV+受试者的预期寿命。然而，中枢神经系统组织中残留的病毒，经历有限的药物暴露与神经艾滋病疾病的进展有关。Impel NeuroPharma与华盛顿大学合作开发了一种新技术，该技术将克服中枢神经系统药物获取的局限性，从而实现最大限度的药物暴露和病毒抑制。这项技术不是将药物沉积到鼻细胞(使用传统的鼻腔给药设备实现的)，而是将药物储存在嗅觉细胞中，并提供直接进入大脑和中枢神经系统的途径，从而提高中枢神经系统的传递效率。拟议中的UW合作将使Impel能够进一步优化和开发这一设备，将抗艾滋病毒药物输送到大脑和中枢神经系统，并在适当的动物模型中对其进行评估。我们设想，该产品将用于抑制中枢神经系统中的病毒，作为目前口服HARRT的辅助药物，这些药物对抑制血液中的艾滋病毒有效。[*缩写列表附在参考文献末尾]公共卫生相关性：拟议中的华盛顿大学合作研究将使Impel NeuroPharma，Inc.能够进一步优化和开发这一设备，将抗艾滋病毒药物输送到大脑和中枢神经系统，并在适当的临床前模型中对其进行评估。我们设想，该产品将用于抑制中枢神经系统中的病毒，作为目前口服HARRT的辅助药物，这些药物对抑制血液中的艾滋病毒有效。

DESCRIPTION (provided by applicant): This program plans to develop a drug delivery system that provides maximum drug exposure and suppress residual human immunodeficiency virus (HIV)* in the brain and tissues of central nervous system (CNS). The advent of highly active antiretroviral combination drug therapies (HAART) has reduced plasma virus concentration to undetectable level and has extended life-expectancy in HIV+ subjects. However, residual virus in the CNS tissues, experiencing limited drug exposure is related to neuroAIDS disease progression. In collaboration with University of Washington, Impel NeuroPharma has developed a novel technology that will overcome limited CNS drug access thereby allowing a maximum drug exposure and viral suppression. Instead of depositing drugs to nasal cells (achieved with traditional nasal delivery devices), this technology deposits drugs in olfactory cells and provides direct access to the brain and CNS, thereby improving the efficiency of CNS delivery. The proposed UW collaboration will allow Impel to further optimize and develop this device for delivery of anti-HIV drugs into the brain and CNS and evaluating it in appropriate animal models. We envisioned that this product will be used to suppress virus in the CNS as an adjunct to the current oral HARRT, which are effective for suppressing HIV in blood. [*Abbreviation list is enclosed at the end of references] PUBLIC HEALTH RELEVANCE: The proposed University of Washington collaborative research will allow Impel NeuroPharma, Inc to further optimize and develop this device for delivery of anti-HIV drugs into the brain and CNS and evaluating it in appropriate preclinical models. We envisioned that this product will be used to suppress virus in the CNS as an adjunct to the current oral HARRT, which are effective for suppressing HIV in blood.